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 2
The TGFβ pathway plays an essential role in embryonic development, organ 21 
homeostasis, tissue repair, and disease1,2. This diversity of tasks is achieved through the 22 
intracellular effector SMAD2/3, whose canonical function is to control activity of target 23 
genes by interacting with transcriptional regulators3. Nevertheless, a complete 24 
description of the factors interacting with SMAD2/3 in any given cell type is still lacking. 25 
Here we address this limitation by describing the interactome of SMAD2/3 in human 26 
pluripotent stem cells (hPSCs). This analysis reveals that SMAD2/3 is involved in 27 
multiple molecular processes in addition to its role in transcription. In particular, we 28 
identify a functional interaction with the METTL3-METTL14-WTAP complex, which 29 
deposits N6-methyladenosine (m6A)4. We uncover that SMAD2/3 promotes binding of 30 
the m6A methyltransferase complex onto a subset of transcripts involved in early cell 31 
fate decisions. This mechanism destabilizes specific SMAD2/3 transcriptional targets, 32 
including the pluripotency factor NANOG, thereby poising them for rapid 33 
downregulation upon differentiation to enable timely exit from pluripotency. 34 
Collectively, these findings reveal the mechanism by which extracellular signalling can 35 
induce rapid cellular responses through regulations of the epitranscriptome. These novel 36 
aspects of TGFβ signalling could have far-reaching implications in many other cell types 37 
and in diseases such as cancer5.  38 
 3
Main 39 
 40 
Activin and Nodal, two members of the TGFβ superfamily, play essential roles in cell fate 41 
decision in hPSCs6–8. Activin/Nodal signalling is necessary to maintain pluripotency, and its 42 
inhibition drives differentiation toward the neuroectoderm lineage6,9,10. Activin/Nodal also 43 
cooperates with BMP and WNT to drive mesendoderm specification11–14. Thus, we used hPSC 44 
differentiation into definitive endoderm as a model system to interrogate the SMAD2/3 45 
interactome during a dynamic cellular process. For that we developed an optimized SMAD2/3 46 
co-immunoprecipitation (co-IP) protocol compatible with mass-spectrometry analyses 47 
(Extended Data Fig. 1a-b and Supplementary Discussion). This method allowed a 48 
comprehensive and unbiased examination of the proteins interacting with SMAD2/3 for the 49 
first time in any given cell type. By examining human embryonic stem cells (hESCs) and 50 
hESCs induced to differentiate towards endoderm (Fig. 1a), we identified 89 SMAD2/3 51 
partners (Fig. 1b, Extended Data Fig. 1c-d, and Supplementary Table 1). Of these, only 11 52 
factors were not shared between hESCs and endoderm differentiating cells (Extended Data 53 
Fig. 1e), suggesting that the SMAD2/3 interactome is largely conserved across these two 54 
lineages (Supplementary Discussion). Importantly, this list included known SMAD2/3 55 
transcriptional and epigenetic cofactors (including FOXH1, SMAD4, SNON, SKI, EP300, 56 
SETDB1, and CREBBP3), which validated our method. Furthermore, we performed functional 57 
experiments on FOXH1, EP300, CREBBP, and SETDB1, which uncovered the essential 58 
function of these SMAD2/3 transcriptional and epigenetic cofactors in hPSC fate decisions 59 
(Extended Data Fig. 2 and 3, and Supplementary Discussion). 60 
 61 
Interestingly, our proteomic experiments also revealed that SMAD2/3 interacts with 62 
complexes involved in functions that have never been associated with TGFβ signalling (Fig. 63 
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1b and Extended Data Fig. 1f), such as ERCC1-XPF (DNA repair) and DAPK3-PAWR 64 
(apoptosis). Most notably, we identified several factors involved in mRNA processing, 65 
modification, and degradation (Fig. 1b), such as the METTL3-METTL14-WTAP complex 66 
(deposition of N6-methyladenosine, or m6A), the PABP-dependent poly(A) nuclease complex 67 
hPAN (mRNA decay), the cleavage factor complex CFIm (pre-mRNA 3’ end processing), and 68 
the NONO-SFPQ-PSPC1 factors (RNA splicing and nuclear retention of defective RNAs). 69 
Overall, these results suggest that SMAD2/3 could be involved in a large number of biological 70 
processes in hPSCs, which include not only transcriptional and epigenetic regulations, but also 71 
novel “non-canonical” molecular functions. 72 
 73 
To further explore this hypothesis, we investigated the interplays between Activin/Nodal and 74 
m6A deposition. m6A is the most common RNA modification, regulating multiple aspects of 75 
mRNA biology including decay and translation4,15–19. However, whether this is a dynamic 76 
event that can be modulated by extracellular cues remains to be established. Furthermore, 77 
while m6A is known to regulate hematopoietic stem cells20,21 and the transition between the 78 
naïve and primed pluripotency states22,23, its function in hPSCs and during germ layer 79 
specification is unclear. We first validated the interaction of SMAD2/3 with METTL3-80 
METTL14-WTAP using co-IP followed by Western Blot in both hESCs and human induced 81 
pluripotent stem cells (hiPSCs; Fig. 2a and Extended Data Fig. 4a-b). Interestingly, inhibition 82 
of SMAD2/3 phosphorylation blocked this interaction (Fig. 2b and Extended Data Fig. 4c). 83 
Proximity ligation assays (PLA) also demonstrated that the interaction occurs at the nuclear 84 
level (Fig. 2c-d). These observations suggest that SMAD2/3 and the m6A methyltransferase 85 
complex interact in an Activin/Nodal signalling-dependent fashion. 86 
 87 
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To investigate the functional relevance of this interaction, we assessed the transcriptome-wide 88 
effects of Activin/Nodal inhibition on the deposition of m6A by performing nuclear-enriched 89 
m6A methylated RNA immunoprecipitation followed by deep sequencing (NeMeRIP-seq; 90 
Extended Data Fig. 5a-d, and Supplementary Discussion). In agreement with previous 91 
reports17,19,24, deposition of m6A onto exons was enriched around stop codons and 92 
transcription start sites, and occurred at a motif corresponding to the m6A consensus sequence 93 
(Extended Data Fig. 5e-g). Assessment of differential m6A deposition revealed that 94 
Activin/Nodal inhibition predominantly resulted in reduced m6A levels in selected transcripts 95 
(Supplementary Table 2; average absolute log2 fold-change of 0.56 and 0.35 for m6A decrease 96 
and increase, respectively). Decrease in m6A deposition was predominantly observed on 97 
peaks located near to stop codons (Extended Data Fig. 5h), a location which has been reported 98 
to decrease the stability of mRNAs16,24,25. Interestingly, transcripts showing reduced m6A 99 
levels after Activin/Nodal inhibition largely and significantly overlapped with genes bound by 100 
SMAD2/3 (Extended Data Fig. 5i), including well-known transcriptional targets such as 101 
NANOG, NODAL, LEFTY1, and SMAD7 (Fig. 2e and Extended Data Fig. 5j). Accordingly, 102 
Activin/Nodal-sensitive m6A deposition was largely associated with transcripts rapidly 103 
decreasing during the exit from pluripotency triggered by Activin/Nodal inhibition (Extended 104 
Data Fig. 6a). Transcripts behaving in this fashion were enriched in pluripotency regulators 105 
and in factors involved in the Activin/Nodal signalling pathway (Supplementary Table 3). On 106 
the other hand, the expression of a large number of developmental regulators associated to 107 
Activin/Nodal-sensitive m6A deposition remained unchanged following Activin/Nodal 108 
inhibition (Extended Data Fig. 6a-c and Supplementary Table 3). Considered together, these 109 
findings establish that Activin/Nodal signalling can regulate m6A deposition on a number of 110 
specific transcripts. 111 
 112 
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We then examined the underlying molecular mechanisms. RNA immunoprecipitation 113 
experiments on nuclear RNAs showed that inhibition of Activin/Nodal signalling impaired 114 
binding of WTAP to multiple m6A-marked transcripts including NANOG and LEFTY1 (Fig. 115 
2f and Extended Data Fig. 4d-e), while SMAD2/3 itself interacted with such transcripts in the 116 
presence of Activin/Nodal signalling (Fig. 2g and Extended Data Fig. 4e). Thus, SMAD2/3 117 
appears to promote the recruitment of the m6A methyltransferase complex onto nuclear 118 
RNAs. Interestingly, recent reports have established that m6A deposition occurs co-119 
transcriptionally and involves nascent pre-RNAs16,26,20. Considering the broad overlap 120 
between SMAD2/3 transcriptional targets and transcripts showing Activin/Nodal-sensitive 121 
m6A deposition (Extended Data Fig 5i), we therefore hypothesized that SMAD2/3 could 122 
facilitate co-transcriptional recruitment of the m6A methyltransferase complex onto nascent 123 
transcripts. Supporting this notion, inhibition of Activin/Nodal signalling mainly resulted in 124 
downregulation of m6A not only on exons, but also onto pre-mRNA-specific features such as 125 
introns and exon-intron junctions (Extended Data Fig. 6d-i and Supplementary Table 2). 126 
Moreover, we observed a correlation in Activin/Nodal sensitivity for m6A peaks within the 127 
same transcript (Extended Data Fig. 6j), suggesting that SMAD2/3 regulates m6A deposition 128 
at the level of a genomic locus rather than on a specific mRNA peak. Nevertheless, a stable 129 
and direct binding of the m6A methyltransferase complex to the DNA could not be detected 130 
(Extended Data Fig. 4f). Thus, co-transcriptional recruitment might rely on indirect and 131 
dynamic interactions with the chromatin. Considering all these results, we propose a model in 132 
which Activin/Nodal signalling promotes co-transcriptional m6A deposition by facilitating the 133 
recruitment of the m6A methyltransferase complex onto nascent mRNAs (Fig. 2h). 134 
 135 
To understand the functional relevance of these regulations in the context of hPSC cell fate 136 
decisions, we performed inducible knockdown experiments for the various subunits of the 137 
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m6A methyltransferase complex27 (Extended Data Fig. 7a-b). As expected, decrease in 138 
WTAP, METTL14, or METTL3 expression reduced the deposition of m6A (Extended Data 139 
Fig 7c-d). Interestingly, prolonged knockdown did not affect pluripotency (Extended Data Fig. 140 
7e-f). However, expression of m6A methyltransferase complex subunits was necessary for 141 
neuroectoderm differentiation induced by the inhibition of Activin/Nodal signalling, while it 142 
was dispensable for Activin-driven endoderm specification (Fig. 3a and Extended Data Fig. 143 
8a-c). Activin/Nodal is known to block neuroectoderm induction by promoting NANOG 144 
expression28, while NANOG is required for the early stages of endoderm specification13. 145 
Therefore, we monitored the levels of this factor during neuroectoderm differentiation. We 146 
observed that both transcript and protein were upregulated following impairment of m6A 147 
methyltransferase activity (Fig. 3b and Extended Data Fig. 9a-b), while mRNA stability was 148 
increased (Extended Data Fig. 9c). These results show that m6A deposition decreases the 149 
stability of the NANOG mRNA to facilitate its downregulation upon loss of Activin/Nodal 150 
signalling, thus facilitating exit from pluripotency and neuroectoderm specification (Extended 151 
Data Fig. 9d). Additional transcriptomic analyses showed that WTAP knockdown resulted in a 152 
global upregulation of genes transcriptionally activated by SMAD2/3 in hESCs, while it 153 
impaired the upregulation of genes induced by Activin/Nodal inhibition during neuroectoderm 154 
differentiation (Fig. 3b, Extended Data Fig. 10a-e, Supplementary Table 4, and  155 
Supplementary Discussion). Importantly, the decrease in WTAP expression also led to the 156 
upregulation of mRNAs marked by m6A (Extended Data Fig. 10f), confirming that WTAP-157 
dependent m6A deposition destabilises mRNAs16,24,25. Moreover, transcripts rapidly 158 
downregulated after Activin/Nodal inhibition were enriched in m6A-marked mRNAs 159 
(Extended Data Fig. 10f). Finally, simultaneous knockdown of METTL3, METTL14, and 160 
WTAP in hESCs resulted in an even stronger dysregulation of Activin/Nodal target transcripts 161 
(Fig. 3c-d and Extended Data Fig. 8d) and defective neuroectoderm differentiation (Fig. 3d 162 
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and Extended Data Fig. 8e-f). Taken together, these results indicate that the interaction of 163 
SMAD2/3 with METTL3-METTL14-WTAP can promote m6a deposition on a subset of 164 
transcripts, including a number of pluripotency regulators that are also transcriptionally 165 
activated by Activin/Nodal signalling. The resulting negative feedback destabilizes these 166 
mRNAs and causes their rapid degradation following inhibition of Activin/Nodal signalling. 167 
This mechanism allows timely exit from pluripotency and induction of neuroectoderm 168 
differentiation (Extended Data Fig. 9d). 169 
 170 
To conclude, this first analysis of the SMAD2/3 interactome reveals novel interplays between 171 
TGFβ signalling and a diversity of cellular processes. Our results suggest that SMAD2/3 could 172 
act as a hub coordinating several proteins known to have a role in mRNA processing and 173 
modification, apoptosis, DNA repair, and transcriptional regulation. This possibility is 174 
illustrated by our results regarding Activin/Nodal-sensitive regulation of m6A. Indeed, 175 
through the interaction between SMAD2/3 and the METTL3-METTL14-WTAP complex, 176 
Activin/Nodal signalling connects transcriptional and epitranscriptional regulations to “poise” 177 
several of its transcriptional targets for rapid degradation upon signalling withdrawal 178 
(Extended Data Fig. 9d). As a result, this avoids overlaps between the pluripotency and 179 
neuroectoderm transcriptional programs, thereby facilitating changes in cell identity. We 180 
anticipate that further studies will clarify the other “non canonical” functions of SMAD2/3, 181 
and will dissect how these are interrelated with chromatin epigenetic, transcriptional, and 182 
epitranscriptional regulations.  183 
 184 
Our findings also clarify and substantially broaden our understanding of the function of m6A 185 
in cell fate decisions. They establish that depletion of m6A in hPSCs does not lead to 186 
differentiation, contrary to predictions from studies in mouse epiblast stem cells22. This could 187 
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imply important functional differences in epitranscriptional regulations between the human 188 
and murine pluripotent state. Moreover, widening the conclusions from previous reports23, we 189 
demonstrate that deposition of m6A is specifically necessary for neuroectoderm induction, but 190 
not for definitive endoderm differentiation. This can be explained by the fact that in contrast to 191 
its strong inhibitory effect on the neuroectoderm lineage28, expression of NANOG is actually 192 
necessary for the early stages of mesendoderm specification13,29. Finally, our results establish 193 
that m6A is a dynamic event directly modulated by extracellular clues such as TGFβ. 194 
Considering the broad importance of TGFβ signalling, the regulation we describe here might 195 
have an essential function in many cellular contexts requiring a rapid response or change in 196 
cell state, such as the inflammatory response or cellular proliferation. 197 
 198 
Supplementary Information is available in the online version of the paper. 199 
 200 
Acknowledgments  201 
We thank Cambridge Genomic Services for help in next generation sequencing. The work was 202 
supported by the European Research Council starting grant “Relieve IMDs” (L.V., S.B., A.B., 203 
P.M.); the Cambridge University Hospitals National Institute for Health Research Biomedical 204 
Research Center (L.V., J.K., A.S.L.); the Wellcome Trust PhD program (A.O., L.Y.); a British 205 
Heart Foundation PhD studentship (FS/11/77/39327 to A.B.); a Grant-in-Aid for JSPS Fellows 206 
(16J08005 to S.N.); and a core support grant from the Wellcome Trust and Medical Research 207 
Council to the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute.  208 
 209 
Author contributions 210 
A.B. conceived the study, performed or contributed to most of the experiments, analysed data, 211 
and wrote the manuscript with input from the other authors. S.B. contributed to study 212 
 10
conception, performed co-IP, NeMeRIP, and RNA-IP experiments, and analysed data. P.M., 213 
I.R.d.l.M, and C.S. analysed NeMeRIP-seq. A.O. performed PLA and co-214 
immunoprecipitations, and analyzed RNA-seq. D.O., L.Y., and J.K. assisted hPSC gene 215 
editing and differentiation; N.C.H. performed quantitative proteomics and data analysis. A.L., 216 
S.N., and R.G. assisted hPSC culture. E.F. optimized NeMeRIP-seq sequencing libraries. J.U. 217 
contributed to study conception and supervision. H.G.S. supervised quantitative proteomics. 218 
S.M. contributed to study conception and supervision, and assisted SMAD2/3 co-IP. L.V. 219 
conceived, supervised, and supported the study, wrote and provided final approval of the 220 
manuscript. 221 
 222 
Author information  223 
Reprints and permissions information is available at www.nature.com/reprints. No competing 224 
financial interests are declared. Correspondence and requests for materials should be 225 
addressed to Ludovic Vallier (lv225@cam.ac.uk). 226 
 227 
References 228 
 229 
1. Wu, M. Y. & Hill, C. S. Tgf-beta superfamily signaling in embryonic development and 230 
homeostasis. Dev. Cell 16, 329–43 (2009). 231 
2. Oshimori, N. & Fuchs, E. The harmonies played by TGF-β in stem cell biology. Cell 232 
Stem Cell 11, 751–64 (2012). 233 
3. Gaarenstroom, T. & Hill, C. S. TGF-β signaling to chromatin: How Smads regulate 234 
transcription during self-renewal and differentiation. Semin. Cell Dev. Biol. 32, 107–8 235 
(2014). 236 
4. Heyn, H. & Esteller, M. An Adenine Code for DNA: A Second Life for N6-237 
 11
Methyladenine. Cell 7, 710–3 (2015). 238 
5. Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFβ in the tumour 239 
microenvironment. Nat. Rev. Cancer 13, 788–799 (2013). 240 
6. Vallier, L., Reynolds, D. & Pedersen, R. A. Nodal inhibits differentiation of human 241 
embryonic stem cells along the neuroectodermal default pathway. Dev. Biol. 275, 403–242 
21 (2004). 243 
7. Vallier, L., Alexander, M. & Pedersen, R. A. Activin/Nodal and FGF pathways 244 
cooperate to maintain pluripotency of human embryonic stem cells. J. Cell Sci. 118, 245 
4495–509 (2005). 246 
8. James, D., Levine, A. J., Besser, D. & Hemmati-Brivanlou, A. TGFbeta/activin/nodal 247 
signaling is necessary for the maintenance of pluripotency in human embryonic stem 248 
cells. Development 132, 1273–82 (2005). 249 
9. Smith, J. R. et al. Inhibition of Activin/Nodal signaling promotes specification of 250 
human embryonic stem cells into neuroectoderm. Dev. Biol. 313, 107–17 (2008). 251 
10. Bertero, A. et al. Activin/Nodal signaling and NANOG orchestrate human embryonic 252 
stem cell fate decisions by controlling the H3K4me3 chromatin mark. Genes Dev. 29, 253 
702–17 (2015). 254 
11. D’Amour, K. A. et al. Efficient differentiation of human embryonic stem cells to 255 
definitive endoderm. Nat. Biotechnol. 23, 1534–41 (2005). 256 
12. Vallier, L. et al. Signaling pathways controlling pluripotency and early cell fate 257 
decisions of human induced pluripotent stem cells. Stem Cells 27, 2655–66 (2009). 258 
13. Teo, A. et al. Pluripotency factors regulate definitive endoderm specification through 259 
eomesodermin. Genes Dev. 2, 238–250 (2011). 260 
14. Kubo, A. et al. Development of definitive endoderm from embryonic stem cells in 261 
culture. Development 131, 1651–62 (2004). 262 
 12
15. Ke, S. et al. A majority of m6A residues are in the last exons, allowing the potential for 263 
3′ UTR regulation. Genes Dev. 29, 2037–53 (2015). 264 
16. Ke, S. et al. m6A mRNA modifications are deposited in nascent pre-mRNA and are not 265 
required for splicing but do specify cytoplasmic turnover. Genes Dev. 31, 990–1006 266 
(2017). 267 
17. Dominissini, D. et al. Topology of the human and mouse m6A RNA methylomes 268 
revealed by m6A-seq. Nature 485, 201–6 (2012). 269 
18. Meyer, K. D. et al. 5’ UTR m6A Promotes Cap-Independent Translation. Cell 163, 270 
999–1010 (2015). 271 
19. Meyer, K. D. et al. Comprehensive analysis of mRNA methylation reveals enrichment 272 
in 3’ UTRs and near stop codons. Cell 149, 1635–46 (2012). 273 
20. Barbieri, I. et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-274 
dependent translation control. Nature 552, 126-131 (2017). 275 
21. Vu, L. P. et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls 276 
myeloid differentiation of normal hematopoietic and leukemia cells. Nat. Med. 23, 277 
1369–1376 (2017). 278 
22. Geula, S. et al. m6A mRNA methylation facilitates resolution of naïve pluripotency 279 
toward differentiation. Science 347, 1002–6 (2015). 280 
23. Batista, P. J. et al. m6A RNA Modification Controls Cell Fate Transition in 281 
Mammalian Embryonic Stem Cells. Cell Stem Cell 15, 707–19 (2014). 282 
24. Schwartz, S. et al. Perturbation of m6A writers reveals two distinct classes of mRNA 283 
methylation at internal and 5’ sites. Cell Rep. 8, 284–96 (2014). 284 
25. Wang, X. et al. N6-methyladenosine-dependent regulation of messenger RNA stability. 285 
Nature 505, 117–20 (2014). 286 
26. Bartosovic, M. et al. N6-methyladenosine demethylase FTO targets pre-mRNAs and 287 
 13
regulates alternative splicing and 3′-end processing. Nucleic Acids Res. 45, 11356–288 
11370 (2017). 289 
27. Bertero, A. et al. Optimized inducible shRNA and CRISPR/Cas9 platforms for in vitro 290 
studies of human development using hPSCs. Development 143, 4405–18 (2016). 291 
28. Vallier, L. et al. Activin/Nodal signalling maintains pluripotency by controlling Nanog 292 
expression. Development 136, 1339–49 (2009). 293 
29. Mendjan, S. et al. NANOG and CDX2 Pattern Distinct Subtypes of Human Mesoderm 294 
during Exit from Pluripotency. Cell Stem Cell 15, 310–325 (2014). 295 
30. Brown, S. et al. Activin/Nodal signaling controls divergent transcriptional networks in 296 
human embryonic stem cells and in endoderm progenitors. Stem Cells 29, 1176–85 297 
(2011). 298 
 299 
Figure legends 300 
 301 
Figure 1. Identification of the SMAD2/3 interactome. 302 
(a) Experimental approach. (b) Interaction network from all known protein-protein 303 
interactions between selected SMAD2/3 partners identified in pluripotent and endoderm cells 304 
(n=3 co-IPs; one-tailed t-test: permutation-based FDR<0.05). Nodes describe: (1) the lineage 305 
in which the proteins were significantly enriched (shape); (2) significance of the enrichment 306 
(size is proportional to the maximum -log p-value); (3) function of the factors (colour). 307 
Complexes of interest are marked. 308 
 309 
Figure 2. Activin/Nodal signalling promotes m6A deposition on specific regulators of 310 
pluripotency and differentiation. 311 
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(a-b) Western blots of SMAD2/3 (S2/3), METTL3 (M3), or control (IgG) 312 
immunoprecipitations (IPs) from nuclear extracts of hESCs (representative of three 313 
experiments). Input is 5% of the material used for IP. In b, IPs were performed from hESCs 314 
maintained in presence of Activin or treated for 1h with SB-431542 (SB; Activin/Nodal 315 
inhibitor). For gel source data, see Supplementary Figure 1. (c) Proximity ligation assays 316 
(PLA) for SMAD2/3 and WTAP in hESCs maintained in presence of Activin or SB 317 
(representative of two experiments). Scale bars: 10μm. DAPI: nuclei. (d) PLA quantification; 318 
the known SMAD2/3 cofactor NANOG was used as positive control10. Mean ± SEM, n=4 319 
PLA. 2-way ANOVA with post-hoc Holm-Sidak comparisons: **=p<0.01, and ***=p<0.001. 320 
(e) Representative results of nuclear-enriched m6A methylated RNA immunoprecipitation 321 
followed by deep-sequencing (m6A NeMeRIP-seq; n=3 cultures, replicates combined for 322 
visualization). Signal represents read enrichment normalized by million mapped reads and 323 
library size. GENCODE gene annotations (red: coding exons; white: untranslated exons; all 324 
potential exons are shown and overlaid), and SMAD2/3 binding sites from ChIP-seq data30 are 325 
shown. (f-g) RNA immunoprecipitation (RIP) experiments for WTAP, SMAD2/3, or IgG 326 
control in hESCs maintained in presence of Activin or treated with SB. RPLP0 and PBGD 327 
were used as negative controls as they present no m6A. f: mean ± SEM, n=3 cultures. 2-way 328 
ANOVA with post-hoc Holm-Sidak comparisons: *=p<0.05, and **=p<0.01. g: mean, n=2 329 
cultures. (h) Model for the mechanism by which SMAD2/3 promotes m6A deposition. P: 330 
phosphorylation; W: WTAP; M14: METTL14. 331 
 332 
Figure 3. The m6A methyltransferase complex antagonizes Activin/Nodal signalling in 333 
hPSCs to promote timely exit from pluripotency. 334 
(a) Immunofluorescence for neural marker SOX1 following neuroectoderm differentiation of 335 
tetracycline (TET)-inducible knockdown (iKD) hESCs (representative of two experiments). 336 
CTR: no TET; DAPI: nuclei. Scale bars: 100μm. (b) qPCR analyses in WTAP iKD hESCs 337 
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subjected to Activin/Nodal signalling inhibition with SB for the indicated time. Act: Activin. 338 
Mean ± SEM, n=3 cultures. 2-way ANOVA with post-hoc Holm-Sidak comparisons: 339 
**=p<0.01, and ***=p<0.001. (c) Western blot validation of multiple inducible knockdown 340 
(MiKD) hESCs for WTAP, METTL3 (M3), and METTL14 (M14). Cells expressing three 341 
copies of the scrambled shRNA (SCR3x) were used as negative control. (d) qPCR analyses in 342 
undifferentiated MiKD hESCs, or following their neuroectoderm differentiation. Mean ± 343 
SEM, n=3 cultures. Two-tailed t-test: **=p<0.01, and ***=p<0.001. 344 
 345 
Methods 346 
 347 
hPSC culture and differentiation 348 
Feeder- and serum-free culture of hESCs (H9/WA09 line; WiCell) and hiPSCs (A1ATR/R;31) 349 
was previously described32. Briefly, cells were plated on gelatin- and MEF medium-coated 350 
plates, and cultured in chemically defined medium (CDM) containing bovine serum albumin 351 
(BSA). CDM was supplemented with 10ng/ml Activin-A and 12ng/ml FGF2 (both from Dr 352 
Marko Hyvonen, Dept. of Biochemistry, University of Cambridge). Cells were passaged every 353 
5-6 days with Collagenase IV, and plated as clumps of 50-100 cells dispensed at a density of 354 
100-150 clumps/cm2. Differentiation was initiated in adherent hESC cultures 48h following 355 
passaging. Definitive endoderm specification was induced for 3 days (unless stated otherwise) 356 
by culturing cells in CDM (without insulin) with 20ng/ml FGF2, 10μM LY294002 (PI3K 357 
inhibitor; Promega), 100ng/ml Activin-A, and 10ng/ml BMP4 (R&D), as previously 358 
described33. Neuroectoderm was induced for 3 days (unless stated otherwise) in CDM-BSA 359 
with 12ng/ml FGF2 and 10μM SB-431542 (Activin/Nodal/TGFβ signalling inhibitor; Tocris), 360 
as previously described34. These same culture conditions were used for Activin/Nodal 361 
signalling inhibition experiments. hPSCs were routinely monitored for absence of karyotypic 362 
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abnormalities and mycoplasma infection. Since hESCs were obtained by a commercial 363 
supplier cell line identification was not performed. hiPSCs were previously generated in house 364 
and genotyped by Sanger sequencing31. 365 
 366 
Molecular cloning 367 
Plasmids carrying inducible shRNAs were generated by cloning annealed oligonucleotides 368 
into the pAAV-Puro_iKD or pAAV-Puro_siKD vectors as previously described27. All shRNA 369 
sequences were obtained from the RNAi Consortium TRC library35 370 
(https://www.broadinstitute.org/rnai/public/). Whenever shRNAs had been validated, the most 371 
powerful ones were chosen (the sequences are reported in Supplementary Table 5). Generation 372 
of a vector containing shRNAs against METTL3, METTL14, and WTAP (cloned in in this 373 
order) was performed by Gibson assembly of PCR products containing individual shRNA 374 
cassettes, as previously described27. The resulting was named pAAV-Puro_MsiKD-375 
M3M14W. Generation of the matched control vector containing three copies of the scrambled 376 
shRNA sequence (pAAV-Puro_MsiKD-SCR3x) was previously described27. 377 
 378 
A targeting vector for the AAVS1 locus carrying constitutively-expressed NANOG was 379 
generated starting from pAAV_TRE-EGFP36. First, the TRE-EGFP cassette was removed 380 
using PspXI and EcoRI, and substituted with the CAG promoter (cut from pR26-381 
CAG_EGFP27 using SpeI and BamHI) by ligating blunt-ended fragments. The resulting vector 382 
(pAAV-Puro_CAG) was then used to clone full-length the NANOG transcript, which includes 383 
its full 5’ and 3’ UTR. The full-length NANOG transcript was constructed from 3 DNA 384 
fragments. The 5’ (1–301bp) and 3’ (1878–2105bp) ends were synthesised (IDT) with 40bp 385 
overlaps corresponding to pGem3Z vector linearised with SmaI. The middle fragment was 386 
amplified from cDNA of H9 hESCs obtained by retrotranscription with poly-T primer using 387 
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primers 5’-TTGTCCCCAAAGCTTGCCTTGCTTT-3’and 5’–CAAAAACGGTAAGAAA-388 
TCAATTAA-3’. The three fragments and the linearized vector were assembled using a 389 
Gibson reaction (NEB) and the sequence of the construct was confirmed by Sanger 390 
sequencing.  The full length NANOG transcript was then subcloned into KpnI- and EcoRV- 391 
digested pAAV-Puro_CAG following KpnI and HincII digestion.  The resulting vector was 392 
named pAAV-Puro_CAG-NANOG. 393 
 394 
Inducible gene knockdown 395 
Clonal inducible knockdown hESCs for METTL3, METTL14, WTAP, or matched controls 396 
expressing a scrambled (SCR) shRNA were generated by gene targeting of the AAVS1 locus 397 
with pAAV-Puro_siKD plasmids, which was verified by genomic PCR, all as previously 398 
described27,36. This same approach was followed to generate multiple inducible knockdown 399 
hESCs for METTL3, METTL14, and WTAP (plasmid pAAV-Puro_MsiKD-M3M14W), or 400 
matched controls expressing three copies of the SCR shRNA (plasmid pAAV-Puro_MsiKD-401 
SCR3x). Inducible knockdown hESCs for SMAD2, FOXH1, SETDB1, EP300, CREBBP, 402 
B2M, and matched controls expressing a scrambled shRNA were generated using pAAV-403 
Puro_iKD vectors27 in hESCs expressing a randomly integrated wild-type tetR. Two wells 404 
were transfected for each shRNA in order to generate independent biological replicates. 405 
Following selection with puromycin, all the resulting targeted cells in each well were pooled 406 
and expanded for further analysis. Given that 20 to 50 clones were obtained for each well, we 407 
refer to these lines as “clonal pools”. Gene knockdown was induced by adding tetracycline 408 
hydrochloride (Sigma-Aldrich) to the culture medium at the concentration of 1μg/ml. Unless 409 
indicated owtherwise in the text or figure legends, inducible knockdown in undifferentiated 410 
hESCs was induced for 5 days, while differentiation assays were performed in hESCs in 411 
which knockdown had been induced for 10 days. 412 
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 413 
Generation of NANOG overexpressing hESCs 414 
NANOG overexpressing H9 hESCs were obtained by zinc finger nuclease (ZFN)-facilitated 415 
gene targeting of the AAVS1 locus with pAAV-Puro_CAG-NANOG. This was performed by 416 
lipofection of the targeting vector and zinc-finger plasmids followed by puromycin selection, 417 
clonal isolation, and genotyping screening of targeted cells, all as previously described27. 418 
 419 
SMAD2/3 co-immunoprecipitation 420 
Approximately 2x107 cells were used for each immunoprecipitation (IP). Unless stated 421 
otherwise, all biochemical steps were performed on ice or at 4°C, and ice-cold buffers were 422 
supplemented with cOmplete Protease Inhibitors (Roche), PhosSTOP Phosphatase Inhibitor 423 
Cocktail (Roche), 1mg/ml Leupeptin, 0.2mM DTT, 0.2mM PMSF, and 10mM sodium 424 
butyrate (all from Sigma-Aldrich). Cells were fed with fresh medium for 2h before being 425 
washed with PBS, scraped in cell dissociation buffer (CDB, Gibco), and pelleted at 250g for 426 
10’. The cell pellet was then washed once with 10 volumes of PBS, and once with 10 volumes 427 
of hypotonic lysis buffer (HLB: 10mM HEPES pH 7.6; 10mM KCl; 2mM MgCl2; 0.2mM 428 
EDTA; 0.2mM EGTA). The pellet was resuspended in 5 volumes of HLB and incubated for 5’ 429 
to induce cell swelling. The resulting cell suspension was homogenized using the “loose” 430 
pestle of a Dounce homogenizer (Jencons Scientific) for 35-50 strokes until plasma membrane 431 
lysis was complete (as judged by microscopic inspection). The nuclei were pelleted at 800g 432 
for 5’, washed once with 10 volumes of HLB, and resuspended in 1.5 volumes of high-salt 433 
nuclear lysis buffer (HSNLB: 20mM HEPES pH 7.6; 420mM NaCl; 2mM MgCl2; 25% 434 
glycerol; 0.2mM EDTA; 0.2mM EGTA). High-salt nuclear extraction was performed by 435 
homogenizing the nuclei using the “tight” pestle of a Dounce homogenizer for 70 strokes, 436 
followed by 45’ of incubation in rotation. The resulting lysate was clarified for 30’ at 16,000g, 437 
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and transferred to a dialysis cassette using a 19-gauge syringe. Dialysis was performed for 4h 438 
in 1l of dialysis buffer (DB: 20mM HEPES pH 7.6; 50mM KCl; 100mM NaCl; 2mM MgCl2; 439 
10% glycerol; 0.2mM EDTA; 0.2mM EGTA) under gentle stirring, and the buffer was 440 
changed once after 2h. After the dialysis, the sample was clarified from minor protein 441 
precipitates for 10’ at 17,000g, and the protein concentration was assessed. 442 
Immunoprecipitations were performed by incubating 0.5mg of protein with 5μg of goat 443 
polyclonal SMAD2/3 antibody (R&D systems, catalogue number: AF3797) or goat IgG 444 
negative control antibody (R&D systems, catalogue number: AB-108-C) for 3h at 4°C in 445 
rotation. This was followed by incubation with 10μl of Protein G-Agarose for 1h. Beads were 446 
finally washed three times with DB, and finally processed for Western blot or mass 447 
spectrometry. This co-immunoprecipitation protocol is referred to as “co-IP2” in the 448 
Supplementary Discussion and in Extended Data Fig. 1. The alternative SMAD2/3 co-449 
immunoprecipitation protocol (co-IP1) was previously described10. 450 
 451 
Mass spectrometry 452 
Label-free quantitative mass spectrometric analysis of proteins co-immunoprecipitated with 453 
SMAD2/3 or from control IgG co-immunoprecipitations was performed on three replicates for 454 
each condition. After immunoprecipitation, samples were prepared as previously described37 455 
with minor modifications. Proteins were eluted by incubation with 50μl of 2M urea and 10mM 456 
DTT for 30’ at RT in agitation. Then, 55mM chloroacetamide was added for 20’ to alkylate 457 
reduced disulphide bonds. Proteins were pre-digested on the beads with 0.4μg of mass 458 
spectrometry-quality trypsin (Promega) for 1h at RT in agitation. The suspension was cleared 459 
from the beads by centrifugation. The beads were then washed with 50ul of 2M Urea, and the 460 
merged supernatants were incubated overnight at RT in agitation to complete digestion. 0.1% 461 
trifluoroacetic acid was then added to inactivate trypsin, and peptides were loaded on C18 462 
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StageTips38. Tips were prepared for binding by sequential equilibration for 2’ at 800g with 463 
50μl methanol, 50μl Solvent B (0.5% acetic acid; 80% acetonitrile), and 50μl Solvent A (0.5% 464 
acetic acid). Subsequently, peptides were loaded and washed twice with Solvent A. Tips were 465 
dry-stored until analysis. Peptides were eluted from the StageTips and separated by reversed-466 
phase liquid chromatography on a 2.5h long segmented gradient using EASY-nLC 1000 467 
(ThermoFisher Scientific). Eluting peptides were ionized and injected directly into a Q 468 
Exactive mass spectrometer (ThermoFisher Scientific). The mass spectrometer was operated 469 
in a TOP10 sequencing mode, meaning that one full mass spectrometry (MS) scan was 470 
followed by higher energy collision induced dissociation (HCD) and subsequent detection of 471 
the fragmentation spectra of the 10 most abundant peptide ions (tandem mass spectrometry; 472 
MS/MS). Collectively, ~160000 isotype patterns were generated resulting from ~6000 mass 473 
spectrometry (MS) runs. Consequently, ~33000 tandem mass spectrometry (MS/MS) spectra 474 
were measured. 475 
 476 
Quantitative mass spectrometry based on dimethyl labelling of samples was performed as 477 
described for label-free quantitative mass spectrometry but with the following differences. 478 
Dimethyl labelling was performed as previously reported39,40. Briefly, trypsin digested protein 479 
samples were incubated with dimethyl labelling reagents (4μl of 0.6M NaBH3CN together 480 
with 4μl of 4% CH2O or CD2O for light or heavy labelling, respectively) for 1h at RT in 481 
agitation. The reaction was stopped by adding 16μl of 1% NH3. Samples were acidified with 482 
0.1% trifluoroacetic acid, and finally loaded on stage-tips. Each immunoprecipitation was 483 
performed twice, switching the labels.  484 
 485 
Analysis of mass spectrometry data 486 
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The raw label-free quantitative mass spectrometric data was analysed using the MaxQuant 487 
software suite41. Peptide spectra were searched against the human database (Uniprot) using the 488 
integrated Andromeda search engine, and peptides were identified with an FDR<0.01 489 
determined by false matches against a reverse decoy database. Peptides were assembled into 490 
protein groups with an FDR<0.01. Protein quantification was performed using the MaxQuant 491 
label-free quantification algorithm requiring at least 2 ratio counts, in order to obtain label free 492 
quantification (LFQ) intensities. Collectively, the MS/MS spectra were matched to ~20000 493 
known peptides, leading to the identification of 3635 proteins in at least one of the conditions 494 
analysed. Statistical analysis of the data was performed using the Perseus software package 495 
(MaxQuant). First, common contaminants and reverse hits were removed, and only proteins 496 
identified by at least two peptides (one of those being unique to the respective protein group) 497 
were considered as high-confidence identifications. Proteins were then filtered for having been 498 
identified in all replicates of at least one condition. LFQ intensities were logarithmized, and 499 
missing intensity values were imputed by representing noise values42. One-tailed t-tests were 500 
then performed to determine the specific interactors in each condition by comparing the 501 
immunoprecipitations with the SMAD2/3 antibody against the IgG negative controls. 502 
Statistical significance was set with a permutation-based FDR<0.05 (250 permutations). Fold-503 
enrichment over IgG controls were calculated from LFQ intensities. 504 
 505 
This same pipeline was used to analyze mass spectrometry data based on dimethyl labelling, 506 
with the following two exceptions. First, an additional mass of 28.03Da (light) or 32.06Da 507 
(heavy) was specified as “labels” at the N-terminus and at lysines. Second, during statistical 508 
analysis of mass spectrometry data the outlier significance was calculated based on protein 509 
intensity (Significance B41), and was required to be below 0.05 for both the forward and the 510 
reverse experiment. 511 
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 512 
Biological interpretation of mass spectrometry data 513 
The SMAD2/3 protein-protein interaction network was generated using Cytoscape v2.8.343. 514 
First, all the annotated interactions involving the SMAD2/3 binding proteins were inferred by 515 
interrogating protein-protein interaction databases through the PSIQUIC Universal Web 516 
Service Client. IMEx-complying interactions were retained and merged by union. Then, a 517 
subnetwork involving only the SMAD2/3 interactors was isolated. Finally, duplicate nodes 518 
and self-loops were removed to simplify visualization. Note that based on our results all the 519 
proteins shown would be connected to SMAD2/3, but such links were omitted to simplify 520 
visualization and highlight those interactions with SMAD2/3 that were already known. 521 
Proteins lacking any link and small complexes of less than three factors were not shown to 522 
improve presentation clarity. Note that since the nodes representing SMAD2 and SMAD3 523 
shared the very same links, they were fused into a single node (SMAD2/3). Functional 524 
enrichment analysis was performed using the Fisher’s exact test implemented in Enrichr44, and 525 
only enriched terms with a Benjamini-Hochberg adjusted p-value<0.05 were considered. For 526 
Gene Ontology (GO) enrichment analysis, the 2015 GO annotation was used. For mouse 527 
phenotype enrichment analysis, the level 3 of the Mouse Genomic Informatics (MGI) 528 
annotation was used. To compare protein abundance in different conditions, a cut-off of 529 
absolute LFQ intensity log2 fold-change larger than 2 was chosen, as label-free mass 530 
spectrometry is at present not sensitive enough to detect smaller changes with confidence37. 531 
 532 
Proximity ligation assay (PLA) 533 
PLA was performed using the Duolink In Situ Red Starter Kit Goat/Rabbit (Sigma-Aldrich). 534 
Cells were cultured on glass coverslips and prepared by fixation in PBS 4% PFA for 10’ at 535 
RT, followed by two gentle washes in PBS. All subsequent incubations were performed at RT 536 
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unless otherwise stated. Samples were permeablilized in PBS 0.25% Triton X-100 for 20’, 537 
blocked in PBS 0.5% BSA for 30’, and incubated with the two primary antibodies of interest 538 
(diluted in PBS 0.5% BSA; see Supplementary Table 6) for 1h at 37°C in a humid chamber. 539 
The Duolink In Situ PLA probes (anti-rabbit minus and anti-goat plus) were mixed and diluted 540 
1:5 in PBS 0.5% BSA, and pre-incubated for 20’. Following two washes with PBS 0.5% BSA, 541 
the coverslips were incubated with the PLA probe solution for 1h at 37°C in a humid chamber. 542 
Single-antibody and probes-only negative controls were performed for each antibody tested to 543 
confirm assay specificity. Coverslips were washed twice in Wash Buffer A for 5’ under gentle 544 
agitation, and incubated with 1x ligation solution supplemented with DNA ligase (1:40 545 
dilution) for 30’ at 37°C in a humid chamber. After two more washes in Wash Buffer A for 2’ 546 
under gentle agitation, coverslips were incubated with 1x amplification solution supplemented 547 
with DNA polymerase (1:80 dilution) for 1h 40’ at 37°C in a humid chamber. Samples were 548 
protected from light from this step onwards. Following two washes in Wash Buffer B for 10’, 549 
the coverslips were dried overnight, and finally mounted on a microscope slide using Duolink 550 
In Situ Mounting Medium with DAPI. Images of random fields of view were acquired using a 551 
LSM 700 confocal microscope (Leica) using a Plan-Apochromat 40x/1.3 Oil DIC M27 552 
objective, performing z-stack with optimal spacing (~0.36μm). Images were automatically 553 
analysed using ImageJ. For this, nuclear (DAPI) and PLA z-stacks were first individually 554 
flattened (max intensity projection) and thresholded to remove background noise. Nuclear 555 
images were further segmented using the watershed function. Total nuclei and PLA spots were 556 
quantified using the analyse particle function of ImageJ, and nuclear PLA spots were 557 
quantified using the speckle inspector function of the ImageJ plugin BioVoxxel. 558 
 559 
RNA immunoprecipitation (RIP) 560 
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Approximately 2x107 cells were used for each RIP. Unless stated otherwise, all biochemical 561 
steps were performed on ice or at 4°C, and ice-cold buffers were supplemented with cOmplete 562 
Protease Inhibitors (Roche) and PhosSTOP Phosphatase Inhibitor Cocktail (Roche). Cells 563 
were fed with fresh culture medium 2h before being washed once with RT PBS and UV cross-564 
linked in PBS at RT using a Stratalinker 1800 at 254nm wavelength (irradiation of 565 
400mJ/cm2). Crosslinked cells were scraped in cell dissociation buffer (CDB, Gibco) and 566 
pelleted at 250g for 5’. The cell pellet was incubated in five volumes of isotonic lysis buffer 567 
(ILB: 10mM Tris-HCl pH 7.5; 3mM CaCl2; 2mM MgCl2; 0.32M sucrose) for 12’ to induce cell 568 
swelling. Then, Triton X-100 was added to a final concentration of 0.3%, and cells were 569 
incubated for 6’ to lyse the plasma membranes. Nuclei were pelleted at 600g for 5’, washed 570 
once with ten volumes of ILB, and finally resuspended in two volumes of nuclear lysis buffer 571 
(NLB: 50mM Tris-HCl pH 7.5; 100mM NaCl; 50mM KCl; 3mM MgCl2; 1mM EDTA; 10% 572 
glycerol; 0.1% Tween) supplemented with 800U/ml RNasin Ribonuclease Plus Inhibitor 573 
(Promega) and 1μM DTT. The nuclear suspension was transferred to a Dounce homogenizer 574 
(Jencons Scientific) and homogenized by performing 70 strokes with a “tight” pestle. The 575 
nuclear lysate was incubated in rotation for 30’, homogenized again by perfoming 30 576 
additional strokes with the tight pestle, and incubated in rotation for 15’ more minutes at RT 577 
after addition of 12.5μg/ml of DNase I (Sigma). The protein concentration was assessed, and 578 
approximately 1mg of protein was used for overnight IP in rotation with the primary antibody 579 
of interest (Supplementary Table 6), or with equal amounts of non-immune species-matched 580 
IgG. 10% of the protein lysate used for IP was saved as pre-IP input and stored at -80°C for 581 
subsequent RNA extraction. IPs were incubated for 1h with 30μl of Protein G-Agarose, then 582 
washed twice with 1ml of LiCl wash buffer (50mM Tris-HCl pH 7.5; 250mM LiCl; 0.1% 583 
Triton X-100; 1mM DTT) and twice with 1ml of NLB. Beads were resuspended in 90μl of 584 
30mM Tris-HCl pH 9.0, and DNase-digested using the RNase-free DNase kit (QIAGEN) by 585 
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adding 10μl of RDD buffer and 2.5μl of DNase. The pre-IP input samples were similarly 586 
treated in parallel, and samples were incubated for 10’ at RT. The reaction was stopped by 587 
adding 2mM EDTA and by heating at 70°C for 5’. Proteins were digested by adding 2μl of 588 
Proteinase K (20mg/ml; Sigma-Aldrich) and by incubating at 37°C for 30’. Finally, RNA was 589 
extracted by using 1ml of TriReagent (Sigma-Aldrich) according to the supplier’s instructions. 590 
The RNA was resuspended in nuclease-free water, and half of the sample was subjected to 591 
retrotranscription using SuperScript II (ThermoFisher) using the manufacturer’s protocol. The 592 
other half was subjected to a control reaction with no reverse transcriptase to confirm 593 
successful removal of DNA contaminants. Samples were quantified by quantitative real-time 594 
PCR (qPCR), and normalized first to the pre-IP input and then to the IgG control using the 595 
ΔΔCt approach (see below). Supplementary Table 5 reports all the primers used. 596 
 597 
Chromatin immunoprecipitation (ChIP) 598 
Approximately 2x107 cells were used for each ChIP, and cells were fed with fresh media 2h 599 
before collection. ChIP was performed using a previously described protocol10,30. Briefly, cells 600 
were cross-linked on plates first with protein-protein crosslinkers (10mM dimethyl 3,3’-601 
dithiopropionimidate dihydrochloride and 2.5mM 3,3’-dithiodipropionic acid di-N-602 
hydroxysuccinimide ester; Sigma-Aldrich) for 15’ at RT, then with 1% formaldehyde for 15’. 603 
Cross-linking was quenched with glycine, after which cells were collected, subjected to 604 
nuclear extraction, and sonicated to fragment the DNA. Following pre-clearing, the lysate was 605 
incubated overnight with the antibodies of interest (Supplementary Table 6) or non-immune 606 
IgG. ChIP was completed by incubation with Protein G-agarose beads followed by subsequent 607 
washes with high salt and LiCl-containing buffers (all exactly as previously described10,30). 608 
Cross-linking was reverted first by adding DTT (for disulphide bridge-containing protein-609 
protein cross-linkers), then by incubating in high salt at high temperatures. DNA was finally 610 
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purified by sequential phenol-chloroform and chloroform extractions. Samples were analysed 611 
by qPCR using the ΔΔCt approach (see Supplementary Table 5 for primer sequences). First, a 612 
region in the last exon of SMAD7 was used as internal control to normalize for background 613 
binding. Secondly, the enrichment was normalized to the one observed in non-immune IgG 614 
ChIP controls. 615 
 616 
m6A dot blot 617 
m6A dot blot was performed with minor modifications to what previously described23. poly-A 618 
RNA was purified from total cellular RNA using the Dynabeads mRNA Purification Kit 619 
(ThermoFisher), diluted in 50μl of RNA loading buffer [RLB: 2.2M formaldehyde; 50% 620 
formamide; 0.5x MOPS buffer (20mM MOPS; 12.5mM CH3COONa; 1.25mM EDTA; pH 621 
7.0)], incubated at 55°C for 15’, and snap cooled on ice. An Amersham Hybond-XL 622 
membrane was rehydrated in water for 3’, then in 10x saline-sodium citrate buffer (SSC: 1.5M 623 
NaCl 150mM Na3C6H5O7; pH 7.0) for 10’, and finally “sandwiched” in a 96-well dot blot 624 
hybridization manifold (ThermoFisher Scientific). Following two washes of the wells with 625 
150μl of 10x SSC, the RNA was spotted on the membrane. After ultraviolet light (UV) cross-626 
linking for 2’ at 254nm using a Stratalinker 1800 (Stratagene), the membrane was washed 627 
once with TBST buffer, and blocked for 1h at RT with Tris-buffered saline Tween buffer 628 
(TBST: 20mM Tris-HCl pH 7.5; 150mM NaCl; 0.1% Tween-20) supplemented with 4% non-629 
fat dry milk. Incubations with the anti-m6A primary antibody (Synaptic System, catalogue 630 
number: 202-111; used at 1μg/ml) and the mouse-HRP secondary antibody (Supplementary 631 
Table 6) were each performed in TBST 4% milk for 1h at RT, and were followed by three 10’ 632 
washes at RT in TBST. Finally, the membrane was incubated with Pierce ECL2 Western 633 
Blotting Substrate, and exposed to X-Ray Super RX Films. 634 
 635 
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m6A nuclear-enriched methylated RNA immunoprecipitation 636 
m6A MeRIP on nuclear-enriched RNA to be analysed by deep sequencing (NeMeRIP-seq) 637 
was performed following modifications of previously described methods23,45. 7.5x107 hESCs 638 
were used for each sample, and three biological replicates per condition were generated. Cells 639 
were fed with fresh medium for 2h before being washed with PBS, scraped in cell dissociation 640 
buffer (CDB, Gibco), and pelleted at 250g for 5’. The cell pellet was incubated in five 641 
volumes of isotonic lysis buffer (ILB: 10mM Tris-HCl pH 7.5; 3mM CaCl2; 2mM MgCl2; 642 
0.32M sucrose; 1,000U/ml RNAsin ribonuclease inhibitor, Promega; and 1mM DTT) for 10’ 643 
to induce cell swelling. Then, Triton X-100 was added to a final concentration of 0.3% and 644 
cells were incubated for 6’ to lyse the plasma membranes. Nuclei were pelleted at 600g for 5’, 645 
washed once with ten volumes of ILB. RNA was extracted from the nuclear pellet using the 646 
RNeasy midi kit (QIAGEN) according to manufacturer’s instructions. Residual contaminating 647 
DNA was digested in solution using the RNAse-free DNase Set from QIAGEN, and RNA was 648 
re-purified by sequential acid phenol-chloroform and chloroform extractions followed by 649 
ethanol precipitation. At this stage, complete removal of DNA contamination was confirmed 650 
by qPCR of the resulting RNA without a retrotranscription step. RNA was then chemically 651 
fragmented in 20μl reactions each containing 20μg of RNA in fragmentation buffer (FB: 652 
10mM ZnCl2; 10mM Tris-HCl pH 7.0). Such reactions were incubated at 95°C for 5’, 653 
followed by inactivation with 50mM EDTA and storage on ice. The fragmented RNA was 654 
then cleaned up by ethanol precipitation. In preparation to the MeRIP, 15μg of anti m6A-655 
antibody (Synaptic Systems, catalogue number: 202-003) or equivalent amounts of rabbit non-656 
immune IgG were cross-linked to 0.5mg of magnetic beads by using the Dynabeads Antibody 657 
Coupling Kit (ThermoFisher Scientific) according to manufacturer’s instructions. Following 658 
equilibration of the magnetic beads by washing with 500μl of binding buffer (BB: 50mM Tris-659 
HCl pH 7.5; 150mM NaCl2; 1% NP-40; 1mM EDTA), MeRIP reactions were assembled with 660 
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300μg of the fragmented RNA in 3ml of BB supplemented with 3000U of RNAsin 661 
ribonuclease inhibitor. Samples were incubated at 7rpm for 1h at RT. 5μg of fragmented RNA 662 
(10% of the amount used for MeRIP) were set aside as pre-MeRIP input control. MeRIP 663 
reactions were washed twice with BB, once with low–salt buffer [LSB: 0.25x SSPE (saline-664 
sodium phosphate-EDTA buffer: 150mM NaCl; 10mM NaHPO4-H2O; 10mM Na2-EDTA; pH 665 
7.4); 37.5mM NaCl2; 1mM EDTA; 0.05% Tween-20), once with high-salt buffer (HSB: 0.25x 666 
SSPE; 137.5mM NaCl2; 1mM EDTA; 0.05% Tween-20), and twice with TE-Tween buffer 667 
(TTB: 10mM Tris-HCl pH 7.4; 1mM EDTA; 0.05% Tween-20). Each wash was performed by 668 
incubating the beads with 500μl of buffer at 7rpm for 3’ at RT. Finally, RNA was eluted from 669 
the beads by four successive incubations with 75μl of elution buffer (EB: 50mM Tris-HCl pH 670 
7.5; 150mM NaCl2; 20mM DTT; 0.1% SDS; 1mM EDTA) at 42°C. Both the RNA from 671 
pooled MeRIP eluates and the pre-MeRIP input were purified and concentrated by sequential 672 
acid phenol-chloroform and chloroform extractions followed by ethanol precipitation. 30μg of 673 
glycogen were added as carrier during ethanol precipitation. RNA was resuspended in 15μl of 674 
ultrapure RNAse-free water. Preparation of DNA libraries for deep sequencing was performed 675 
using the TruSeq Stranded total RNA kit (Illumina) according to manufacturer’s instructions 676 
with the following exceptions: (1) Ribo-Zero treatment was performed only for pre-NeMeRIP 677 
samples, as ribosomal RNA contamination in m6A NeMeRIP samples was minimal; (1) since 678 
samples were pre-fragmented, the fragmentation step was bypassed and 30ng of RNA for each 679 
sample were used directly for library prep; (3) due to the small size of the library, a 2-fold 680 
excess of Ampure XP beads was used during all purification steps in order to retain small 681 
fragments; (4) due to the presence of contaminating adapter dimers, the library was gel 682 
extracted using gel safe stain and a dark reader in order to remove fragments smaller than 683 
~120bp. Pooled libraries were diluted and denatured for sequencing on the NextSeq 500 684 
(Illumina) according to the manufacturer’s instructions. Samples were pooled so as to obtain 685 
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>30M unique clusters per sample. The PhiX control library (Illumina) was spiked into the 686 
main library pool at 1% vol/vol for quality control purposes. Sequencing was performed using 687 
a high output flow cell with 2x75 cycles of sequencing, which provided ~800M paired end 688 
reads from ~400M unique clusters from each lane. Overall, an average of ~33M and ~54M 689 
paired-end reads were generated for m6A MeRIP and pre-MeRIP samples, respectively. 690 
 691 
Samples for m6A MeRIP to be analysed by qPCR (NeMeRIP-qPCR) were processed as just 692 
described for NeMeRIP-seq, but starting from 2.5x107 cells. MeRIP from cytoplasmic RNA 693 
was performed from RNA extracted from the cytoplasmic fraction of cells being processed for 694 
NeMeRIP. In both cases, MeRIP was performed as for NeMeRIP-seq, but using 2.5μg of anti 695 
m6A-antibody (or equivalent amounts of rabbit non-immune IgG) and 50μg of RNA in 500μl 696 
of BB supplemented with 500U of RNAsin ribonuclease inhibitor. At the end of the protocol, 697 
RNA was resuspended in 15μl of ultrapure RNAse-free water. For m6A MeRIP on total RNA, 698 
the protocol just described was followed exactly, with the exception that the subcellular 699 
fractionation step was bypassed, and that total RNA was extracted from 5x106 cells. For m6A 700 
MeRIP on mRNA, poly-A RNA was purified from 75μg of total RNA using the Dynabeads 701 
mRNA Purification Kit, and 2.5μg of the resulting mRNA were used for chemical 702 
fragmentation and subsequent MeRIP with 1μg of anti-m6A antibody. At the end of all these 703 
protocols, cDNA synthesis was performed using all of the MeRIP material in a 30μl reaction 704 
containing 500ng random primers, 0.5mM dNTPs, 20U RNaseOUT, and 200U of SuperScript 705 
II (all from Invitrogen), all according to manufacturer’s instructions. cDNA was diluted 10-706 
fold, and 5μl were used for qPCR using KAPA Sybr Fast Low Rox (KAPA Biosystems). For 707 
each gene of interest, two primer pairs were designed either against the region containing the 708 
m6A peak23, or against a negative region (portion of the same transcript lacking the m6A 709 
peak; Supplementary Table 5). Results of MeRIP-qPCR for each gene were then calculated 710 
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using the ΔΔCt approach by using the negative region to normalize both for the expression 711 
level of the transcript of interest and for background binding. 712 
 713 
Analysis of NeMeRIP-seq data 714 
QC of raw sequencing data was assessed using Trimmomatic v0.3546, with parameters 715 
‘LEADING:3 TRAILING:3 SLIDINGWINDOW:5:10 MINLEN:40’. Reads were aligned to 716 
GRCh38 human genome assembly using TopHat 2.0.1347 with parameters ‘--library-type fr-717 
firststrand –transcriptome-index’ and the Ensembl GRCh38.83 annotation. Identification of 718 
novel splice junctions was allowed. Paired-end and unpaired reads passing QC were 719 
concatenated and mapped in 'single-end' mode in order to be used with MeTDiff48, which only 720 
supports single-end reads. Reads with MAPQ<20 were filtered out. m6A peak calling and 721 
differential RNA methylation in the exome was assessed using MetDiff48 with pooled inputs 722 
for each conditions, GENE_ANNO_GTF=GRCh38.83, MINIMAL_MAPQ=20, and rest of 723 
parameters as default (PEAK_CUTOFF_FDR=0.05; DIFF_PEAK_CUTOFF_FDR=0.05). 724 
MetDiff calculates p-values by a likelihood ratio test, then adjust them to FDR by Benjamini-725 
Hochberg correction. An additional cut-off of absolute fold-change>1.5 (meaning an absolute 726 
log2 fold-change>0.585) was applied for certain analyses as specified in the figure legends or 727 
tables. Given known differences between epitranscriptome maps as a function of pipeline49,50, 728 
we confirmed the site-specific and general trends in our data by using an additional pipeline45. 729 
For this, MACS251 was used with parameters ‘-q 0.05 --nomodel --keep-dup all’ in m6A 730 
NeMeRIP-seq and paired inputs after read alignment with Bowtie 2.2.2.0 (reads with 731 
MAPQ<20 were filtered out). Peaks found in at least two samples were kept for further 732 
processing, and a consensus MACS2 peak list was obtained merging those located in a 733 
distance closer than 100bp. The MetDiff and MACS2 peak lists largely overlapped (Extended 734 
Data Fig. 5d), and differed primarily because MACS2 identifies peaks throughout the genome 735 
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while MetDiff only identifies peaks found on the exome (Extended Data Fig. 5c). For the 736 
following analyses focused on exonic m6A peaks we considered a stringent consensus list of 737 
only those MetDiff peaks overlapping with MACS2 peaks (Supplementary Table 2, “exon 738 
m6a”). We assessed the reproducibility of m6A NeMeRIP-seq triplicates in peak regions using 739 
the Bioconductor package fCCAC v1.0.052. Hierarchical clustering (euclidean distance, 740 
complete method) of F values corresponding to first two canonical correlations divided the 741 
samples in Activin and SB clusters. Normalized read coverage files were generated using the 742 
function 'normalise_bigwig' in RSeQC-2.653 with default parameters. The distribution of m6A 743 
coverage across genomic features was plotted using the Bioconductor package RCAS54 744 
with sampleN=0 (no downsampling) and flankSize=2500. Motif finding on m6A peaks was 745 
performed using DREME with default parameters55. For visualization purposes, the three 746 
biological replicates were combined. The Biodalliance genome viewer56 was used to generate 747 
figures. Gene expression in this experiment was estimated from the pre-MeRIP input samples 748 
(which represent an RNA-seq sample on nuclear-enriched RNA species). Quantification, 749 
normalisation of read counts, and estimation of differential gene expression in pre-MeRIP 750 
input samples were performed using featureCounts57 and DESeq258. For assessment 751 
of reproducibility regularised log transformation of count data was computed, and  biological 752 
replicates of input samples of the same condition clustered together in the PC 753 
space59. Estimation of differential m6A deposition onto each peak in NeMeRIP samples 754 
versus input controls was performed using an analogous approach. Functional enrichment 755 
analysis of m6A-marked transcripts was performed using Enrichr44, as described above for 756 
mass-spectrometry data. The coordinates of SMAD2/3 ChIP-seq peaks in hESCs30 were 757 
transferred from their original mapping on hg18 to hg38 using liftOver. Overlap of the 758 
resulting intervals with m6A peaks significantly downregulated after 2h of SB was determined 759 
using GAT60 with default parameters. SMAD2/3 binding sites were assigned to the closest 760 
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gene using the annotatePeaks.pl function from the HOMER suite61 with standard parameters. 761 
The significance in the overlap between the resulting gene list and that of genes encoding for 762 
transcripts with m6A peaks significantly downregulated after 2h of SB was calculated by a 763 
hypergeometric test where the population size corresponded to the number of genes in the 764 
standard Ensemble annotation (GRCh38.83). 765 
 766 
m6A peaks on introns were identified in three steps (Extended Data Fig 6d). First, MetDiff 767 
was used to simultaneously perform peak calling and differential methylation analysis. Since 768 
MetDiff only accepts a transcriptome GTF annotation as an input to determine the genomic 769 
space onto which it identifies m6A peaks, in order to determine peaks onto introns we 770 
followed the strategy recommended by the package developers of running the software using a 771 
custom transcriptome annotation that includes introns48,62. This “extended” transcriptome 772 
annotation was built using Cufflinks 2.2.163 with parameters '--library-type=fr-firststrand -m 773 
100 -s 50’ and guided by the Ensemble annotation (GRCh38.83). This was assembled using all 774 
pre-NeMeRIP input reads available. The result was an extended transcriptome annotation 775 
including all of the transcribed genome that could be detected and reconstructed from our 776 
nuclear-enriched input RNA samples, thus including most expressed introns. Then, MetDiff 777 
was run using this extended annotation as input for GENE_ANNO_GTF, pooled inputs for 778 
each conditions, WINDOW_WIDTH=40, SLIDING_STEP=20, 779 
FRAGMENT_LENGHT=250, PEAK_CUTOFF_PVALUE=1E-03, 780 
FOLD_ENRICHMENT=2, MINIMAL_MAPQ=20, and all other parameters as default). In a 781 
second step, the peaks identified by MetDiff were filtered for robustness by requiring that they 782 
overlapped with MACS2 peak calls, exactly as for exome-focused MetDiff peak calls 783 
(Extended Data Fig. 5d). Finally, only peaks that strictly did not overlap with any exon based 784 
on the Human Gencode annotation V.27 were retained to ensure specificity of mapping to 785 
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introns (Supplementary Table 2; “intron m6A”). MetDiff scores for the resulting peak list 786 
were used to assess differential m6A deposition based on the cutoff of FDR<0.05.  787 
 788 
m6A exon peaks spanning splice sites were selected from those identified both by the MetDiff 789 
analysis on the transcribed genome that was just described and by MACS2. Among these 790 
peaks, those presenting sequencing reads overlapping to both an exon and 791 
upstream/downstream intron were further selected (Supplementary Table 2; “splice-site 792 
spanning m6A”). Peaks accomplishing MetDiff-calculated FDR<0.05 and absolute fold-793 
change>1.5 (log2 fold-change<-0.585) were used to create densities of RPKM-normalized 794 
reads inside exons and in the ± 500bp surrounding introns. Biological replicates were merged 795 
and depicted on 10bp-binned heatmaps for visualization purposes. To study the covariation of 796 
m6A peaks inside each transcriptional unit, the exonic peak with the greatest down regulated 797 
MetDiff fold-change was compared to the mean fold-change of the rest of m6A peaks found 798 
within the gene (both on exons and on introns). The resulting correlation was significant 799 
(p<2E-16; adjusted R2=0.2221) 800 
 801 
RNA sequencing (RNA-seq) 802 
Polyadenylated (poly-A) purified opposing strand-specific mRNA library libraries were 803 
prepared from 200ng of total RNA using the TruSeq Stranded mRNA HT sample preparation 804 
kit (Illumina). Samples were individually indexed for pooling using a dual-index strategy. 805 
Libraries were quantified both with a Qubit (ThermoFisher Scientific) and by qPCR using the 806 
NGS Library Quantification Kit (KAPA Biosystems). Libraries were then normalized and 807 
pooled. Pooled libraries were diluted and denatured for sequencing on the NextSeq 500 808 
(Illumina) according to the manufacturer’s instructions. Samples were pooled so as to obtain 809 
>30M unique clusters per sample (18 samples were split in two runs and multiplexed across 4 810 
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lanes per run). The PhiX control library (Illumina) was spiked into the main library pool at 1% 811 
vol/vol for quality control purposes. Sequencing was performed using a high output flow cell 812 
with 2x75 cycles of sequencing, which provided ~800M paired end reads from ~400M unique 813 
clusters from each run. Overall, a total of ~80M paired end reads per sample were obtained.  814 
 815 
Analysis of RNA-seq data 816 
Reads were trimmed using Sickle64 with ‘q=20  and l=30’. To prepare for reads alignment, the 817 
human transcriptome was built with TopHat2 v2.1.044 based on Bowtie v2.2.665 by using the 818 
human GRCh38.p6 as reference genome, and the Ensembl gene transfer format (GTF) as 819 
annotation (http://ftp.ensembl.org/pub/release-83/gtf/homo_sapiens/). All analyses were 820 
performed using this transcriptome assembly. Alignment was performed using TopHat2 with 821 
standard parameters. Using Samtools view66, reads with MAPQ>10 were kept for further 822 
analyses. Subsequent quantitative data analysis was performed using SeqMonk67. The RNA-823 
seq pipeline was used to quantify gene expression as reads per million mapped reads (RPM), 824 
and differential expression analysis for binary comparisons was performed using the R 825 
package DESeq258. A combined cut-off of negative binomial test p<0.05 and abs.FC>2 was 826 
chosen. Analysis of differentially expressed transcripts across all samples was done using the 827 
R/Bioconductor timecourse package68. The Hotelling T2 score for each transcript was 828 
calculated using the MB.2D function with all parameters set to their default value. Hotelling 829 
T2 scores were used to rank probes according to differential expression across the time-course, 830 
and the top 5% differentially expressed transcripts were selected for complete Euclidean 831 
hierarchical clustering (k-means preprocessing; max of 300 clusters) using Perseus software. 832 
Z-scores of log2 normalized expression values across the timecourse were calculated and used 833 
for this analysis. 8 gene clusters were defined, and gene enrichment analysis for selected 834 
clusters was performed using the Fisher’s exact test implemented in Enrichr44. Only enriched 835 
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terms with a Benjamini-Hochberg adjusted p-value<0.05 were considered. Principal 836 
component analysis (PCA) was performed on the same list of top 5% differentially expressed 837 
transcripts using Perseus. 838 
 839 
Quantitative real-time PCR (qPCR) 840 
Cellular RNA was extracted using the GenElute Mammalian Total RNA Miniprep Kit and the 841 
On-Column DNase I Digestion Set (both from Sigma-Aldrich) following manufacturer’s 842 
instructions. 500ng of RNA was used for complementary DNA (cDNA) synthesis using 843 
SuperScript II (Invitrogen) according to manufacturer’s instructions. cDNA was diluted 30-844 
fold, and 5μl were used for qPCR using SensiMix SYBR low-ROX (Bioline) and 150nM 845 
forward and reverse primers (Sigma-Aldrich; see Supplementary Table 5 for primer 846 
sequences). Samples were run in technical duplicates on 96-well plates on a Stratagene Mx-847 
3005P (Agilent), and results were analysed using the delta-delta cycle threshold (ΔΔCt) 848 
approach69 using RPLP0 as housekeeping gene. The reference sample used as control to 849 
calculate the relative gene expression is indicated in each figure or figure legend. In cases 850 
where multiple control samples were used as reference, the average ΔCt from all controls was 851 
used when calculating the ΔΔCt. All primers were designed using PrimerBlast 852 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and were validated to have a qPCR 853 
efficiency >98% and to produce a single PCR product. 854 
 855 
mRNA stability measurements 856 
RNA stability was measured by collecting RNA samples at different time points following 857 
transcriptional inhibition with 1 μg/ml actinomycin D (Sigma-Aldrich). Following qPCR 858 
analyses using equal amounts of mRNA, gene expression was expressed as relative to the 859 
beginning of the experiment (no actinomycin D treatment). The data was then fit to a one-860 
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phase decay regression model70, and statistical differences in mRNA half-live were evaluated 861 
by comparing the model fits by extra sum-of-squares F test. 862 
 863 
Western blot 864 
Samples were prepared by adding Laemmli buffer (final concentration of 30mM Tris-HCl pH 865 
6.8, 6% glycerol, 2% sodium dodecyl sulphate/SDS, 0.02% bromophenol blue, and 0.25% β-866 
mercaptoethanol), and were denatured at 95°C for 5’. Proteins were loaded and run on 4-12% 867 
NuPAGE Bis-Tris Precast Gels (Invitrogen), then transferred to polyvinylidene fluoride 868 
(PVDF) membranes by liquid transfer using NuPAGE Transfer buffer (Invitrogen). 869 
Membranes were blocked for 1h at RT in PBS 0.05% Tween-20 (PBST) supplemented with 870 
4% non-fat dried milk, and incubated overnight at 4°C with the primary antibody diluted in the 871 
same blocking buffer (Supplementary Table 6). After three washes in PBST, membranes were 872 
incubated for 1h at RT with horseradish peroxidase (HRP)-conjugated secondary antibodies 873 
diluted in blocking buffer (Supplementary Table 6), then further washed three times with 874 
PBST before being incubated with Pierce ECL2 Western Blotting Substrate (Thermo) and 875 
exposed to X-Ray Super RX Films (Fujifilm). 876 
 877 
Immunofluorescence 878 
Cells were fixed for 20’ at 4°C in PBS 4% PFA, rinsed three times with PBS, and blocked and 879 
permeabilized for 30’ at RT using PBS with 10% donkey serum (Biorad) and 0.1% Triton X-880 
100 (Sigma-Aldrich). Primary antibodies (Supplementary Table 6) were diluted in PBS 1% 881 
donkey serum 0.1% Triton X-100 and incubated overnight at 4°C. This was followed by three 882 
washes with PBS and by further incubation with AlexaFluor secondary antibodies 883 
(Supplementary Table 6) for 1h at RT protected from light. Cells were finally washed three 884 
times with PBS, and 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) 885 
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was added to the first wash to stain nuclei. Images were acquired using a LSM 700 confocal 886 
microscope (Leica). 887 
 888 
Flow cytometry 889 
Single cell suspensions were prepared by incubation in cell cell dissociation buffer (CDB; 890 
Gibco) for 10’ at 37° followed by extensive pipetting. Cells were washed twice with PBS and 891 
fixed for 20’ at 4°C with PBS 4% PFA. After three washes with PBS, cells were first 892 
permeabilized for 20’ at RT with PBS 0.1% Triton X-100, then blocked for 30’ at RT with 893 
PBS 10% donkey serum. Primary and secondary antibodies incubations (Supplementary Table 894 
6) were performed for 1h each at RT in PBS 1% donkey serum 0.1% Triton X-100, and cells 895 
were washed three times with this same buffer after each incubation. Flow cytometry was 896 
performed using a Cyan ADP flow-cytometer, and at least 10,000 events were recorded. Data 897 
analysis was performed using FlowJo X. 898 
 899 
Statistics and reproducibility 900 
Unless described otherwise in a specific section of the Methods, standard statistical analyses 901 
were performed using GraphPad Prism 7 using default parameters. The type and number of 902 
replicates, the statistical test used, and the test results are described in the figure legends. The 903 
level of significance in all graphs is represented as it follows (p denotes the p-value): 904 
*=p<0.05, **=p<0.01, and ***=p<0.001. Test assumptions (e.g. normal distribution) were 905 
confirmed where appropriate. For analyses with n<10 individual data points are shown, and 906 
the mean ± SEM is reported for all analyses with n>2. The mean is reported when n=2, and no 907 
other statistics were calculated for these experiments due to the small sample size. No 908 
experimental samples were excluded from the statistical analyses. Sample size was not pre-909 
determined through power calculations, and no randomization or investigator blinding 910 
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approaches were implemented during the experiments and data analyses. When representative 911 
results are presented, the experiments were reproduced in at least two independent cultures, 912 
and the exact number of such replications is detailed in the figure legend. 913 
 914 
Code availability 915 
Custom bioinformatics scripts used to analyse the data presented in the study have been 916 
deposited to GitHub (http://github.com/pmb59/neMeRIP-seq). 917 
 918 
Data availability 919 
The mass spectrometry proteomics data that support the findings of this study have been 920 
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the 921 
identifier PXD005285. Nucleotide sequencing data that support the findings of this study have 922 
been deposited to Array Express with identifiers E-MTAB-5229 and E-MTAB-5230. Source 923 
data for the graphical representations found in all Figures and Extended Data Figures are 924 
provided in the Supplementary Information of this manuscript (Source Data Table Figure 1 925 
and 3, and Source Data Extended Data Figure 1 to 10). Electrophoretic gel source data 926 
(uncropped scans with size marker indications) are presented in Supplementary Figure 1. 927 
Supplementary Tables 1 to 4 provide the results of bioinformatics analyses described in the 928 
text and figure legends. All other data that supports the findings of this study are available 929 
from the corresponding author upon reasonable request. 930 
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Extended Data Figure legends 1031 
 1032 
Extended Data Figure 1. Optimized SMAD2/3 co-immunoprecipitation protocol to define 1033 
its interactome in hPSCs and early endoderm cells. 1034 
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(a) Western blots of SMAD2/3 or control (IgG) immunoprecipitations (IPs) from nuclear 1035 
extracts of hESCs following the co-IP1 or co-IP2 protocols. Input is 5% of the material used 1036 
for IP. Results are representative of two independent experiments. For gel source data, see 1037 
Supplementary Figure 1. (b) Scatter plots of the log2 ratios of label-free quantification (LFQ) 1038 
intensities for proteins identified by quantitative mass spectrometry in SMAD2/3 co-IPs 1039 
compared with IgG negative control co-IPs. The experiments were performed from nuclear 1040 
extracts of hESCs. The SMAD2/3 and IgG negative control co-IPs were differentially labelled 1041 
post-IP using the dimethyl method, followed by a combined run of the two samples in order to 1042 
compare the abundance of specific peptides and identify enriched ones. The values for 1043 
technical dye-swap duplicates are plotted on different axes, and proteins whose enrichment 1044 
was significant (significance B<0.01) are shown in black and named. As a result of this 1045 
comparison between the two co-IP protocols, co-IP2 was selected for further experiments (see 1046 
Supplementary Discussion). (c) Volcano plots of statistical significance against fold-change 1047 
for proteins identified by label-free quantitative mass spectrometry in SMAD2/3 or IgG 1048 
negative control IPs in pluripotent hESCs or early endoderm (see Fig. 1a). The black lines 1049 
indicate the threshold used to determine specific SMAD2/3 interactors, which are located to 1050 
the right (n=3 co-IPs; one-tailed t-test: permutation-based FDR<0.05). (d) Selected results of 1051 
the analysis described in panel c for SMAD2, SMAD3, and selected known bona fide 1052 
SMAD2/3 binding partners (full results can be found in Supplementary Table 1). (e) Average 1053 
label free quantification (LFQ) intensity log2 ratios in endoderm (Endo) and pluripotency 1054 
(Pluri) for all SMAD2/3 interactors. Differentially enriched proteins are shown as green and 1055 
blue bars. (f) Selected results from gene ontology (GO) enrichment analysis, and enrichment 1056 
analysis for mouse phenotypes annotated in the Mouse Genomics Informatics (MGI) database. 1057 
All SMAD2/3 putative interacting proteins were considered for this analysis (n=89 proteins; 1058 
Fisher’s exact test followed by Benjamini-Hochberg correction for multiple comparisions). 1059 
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For each term, its rank in the analysis, the adjusted p-value, and the number of associated 1060 
genes are reported. 1061 
 1062 
Extended Data Figure 2. Functional characterization of SMAD2/3 transcriptional and 1063 
epigenetic cofactors in hPSCs. 1064 
(a) Western blots of SMAD2/3 or control (IgG) immunoprecipitations (IPs) from nuclear 1065 
extracts of pluripotent hESCs (Pluri), or hESCs differentiated into endoderm for 36h (Endo). 1066 
Input is 5% of the material used for IP. Results are representative of two independent 1067 
experiments. (b) Schematic of the experimental approach for the generation of tetracycline-1068 
inducible knockdown (iKD) hESC lines for SMAD2/3 cofactors. (c) qPCR screening of iKD 1069 
hESCs cultured in absence (CTR) or presence of tetracycline for 3 days (TET). Three distinct 1070 
shRNAs were tested for each gene. Expression is shown as normalized on the average level in 1071 
hESCs carrying negative control shRNAs (scrambled, SCR, or against B2M) and cultured in 1072 
absence of tetracycline. The mean is indicated, n=2 independent clonal pools. Note than for 1073 
the B2M shRNA only the SCR shRNA was used as negative control. shRNAs selected for 1074 
further experiments are circled. (d) Phase contrast images of iKD hESCs expressing the 1075 
indicated shRNAs (sh) and cultured in presence of tetracycline for 6 days to induce 1076 
knockdown. Scale bars: 400μm. Results are representative of two independent experiments. 1077 
(e) Immunofluorescence for the pluripotency factor NANOG in iKD hESCs for the indicated 1078 
genes cultured in absence (CTR) or presence of tetracycline (TET) for 6 days. DAPI: nuclear 1079 
staining; scale bars: 400μm. Results are representative of two independent experiments. (f) 1080 
Heatmap summarizing qPCR analyses of iKD hESCs cultured as in panel e. log2 fold-changes 1081 
(FC) are compared to SCR CTR (n=2 clonal pools). Germ layer markers are grouped in boxes 1082 
(green: endoderm; red: mesoderm; blue: neuroectoderm). 1083 
 1084 
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Extended Data Figure 3. Functional characterization of SMAD2/3 transcriptional and 1085 
epigenetic cofactors during endoderm differentiation. 1086 
(a) qPCR validation of inducible knockdown (iKD) hESCs in pluripotency (PLURI) and 1087 
following endoderm differentiation (ENDO). Pluripotent cells were cultured in absence (CTR) 1088 
or presence of tetracycline (TET) for 6 days. For endoderm differentiation, tetracycline 1089 
treatment was initiated in undifferentiated hESCs for 3 days in order to ensure gene 1090 
knockdown at the start of endoderm specification, and was then maintained during 1091 
differentiation (3 days). For each gene, the shRNA resulting in the strongest level of 1092 
knockdown in hPSCs was selected (refer to Extended Data Fig. 2). Expression is shown as 1093 
normalized to the average level in pluripotent hESCs carrying a scrambled (SCR) control 1094 
shRNAs and cultured in absence of tetracycline. The mean is indicated, n=2 independent 1095 
clonal pools. (b) Immunofluorescence for the endoderm marker SOX17 following endoderm 1096 
differentiation of iKD hESCs expressing the indicated shRNAs (sh) and cultured as described 1097 
in panel a. DAPI shows nuclear staining. Scale bars: 400μm. Results are representative of two 1098 
independent experiments. (c) qPCR following endoderm differentiation of iKD hESCs. The 1099 
mean is indicated, n=2 independent clonal pools. (d) Table summarizing the phenotypic 1100 
results presented in Extended Data Fig. 2 and in this figure. E: endoderm; N: neuroectoderm; 1101 
M: mesoderm. 1102 
 1103 
Extended Data Figure 4. Mechanistic insights into the functional interaction between 1104 
SMAD2/3 and the m6A methyltransferase complex. 1105 
(a-c) Western blots of SMAD2/3 (S2/3), METTL3 (M3), METTL14 (M14), or control (IgG) 1106 
immunoprecipitations (IPs) from nuclear extracts of hPSCs (hESCs for panels a and c, and 1107 
hiPSCs for panel b). Input is 5% of the material used for IP. In c, IPs were performed from 1108 
hPSCs maintained in presence of Activin or treated for 1h with the Activin/Nodal inhibitor 1109 
SB-431542 (SB). Results are representative of three (panel a) or two (panels b-c) independent 1110 
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experiments. (d) qPCR validation of hESCs constitutively overexpressing NANOG (NANOG 1111 
OE) following gene targeting of the AAVS1 locus with pAAV-Puro_CAG-NANOG. Parental 1112 
wild-type H9 hESCs (H9) were analysed as negative control. Cells were cultured in presence 1113 
of Activin or treated with SB for the indicated time points. The mean is indicated, n=2 1114 
cultures. NANOG OE cells are resistant to downregulation of NANOG following 1115 
Activin/Nodal inhibiton. (e) RNA immunoprecipitation (RIP) experiments for WTAP, 1116 
SMAD2/3 (S2/3), or IgG control in NANOG overexpressing hESCs maintained in presence of 1117 
Activin or treated for 2 hours with SB. Enrichment of the indicated transcripts was measured 1118 
by qPCR and expressed over background levels observed in IgG RIP in presence of Activin. 1119 
RPLP0 was tested as a negative control transcript. Mean ± SEM, n=3 cultures. Significance 1120 
was tested for differences versus Activin (left panel) or versus IgG (right panel) by 2-way 1121 
ANOVA with post-hoc Holm-Sidak comparisons: *=p<0.05, **=p<0.01, and ***=p<0.001. 1122 
(f) Chromatin immunoprecipitation (ChIP) qPCR in hESCs for the indicated proteins or for 1123 
the negative control ChIP (IgG). qPCR was performed for validated genomic SMAD2/3 1124 
binding sites associated to the indicated genes10,30. hESCs were cultured in presence of Activin 1125 
or treated for 2h with SB. The enrichment is expressed as normalized levels to background 1126 
binding observed in IgG ChIP. The mean is indicated, n=2 technical replicates. Results are 1127 
representative of three independent experiments. 1128 
 1129 
Extended Data Figure 5. Monitoring the changes in m6A deposition rapidly induced by 1130 
Activin/Nodal inhibition. 1131 
(a-b) m6A methylated RNA immunoprecipitation (MeRIP) qPCR results from purified 1132 
mRNA, total cellular RNA, or cellular RNA species separated following nuclear/cytoplasmic 1133 
subcellular fractionation. hESCs were cultured in pluripotency-maintaining conditions 1134 
containing Activin, or subjected to Activin/Nodal inhibition for 2h with SB-431542 (SB). IgG 1135 
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MeRIP experiments were performed as negative controls. The mean is indicated, n=2 1136 
technical replicates. Differences between Activin and SB-treated cells were observed only in 1137 
the nuclear-enriched fraction. Therefore, the nuclear-enriched MeRIP protocol (NeMeRIP) 1138 
was used for subsequent experiments (refer to the Supplementary Discussion). Results are 1139 
representative of two independent experiments. (c) Overlap with the indicated genomic 1140 
features of m6A peaks identified by NeMeRIP-seq using two different bioinformatics 1141 
pipelines in which peak calling was performed using MetDiff or MACS2. For each pipeline, 1142 
the analyses were performed on the union of peaks identified from data obtained in hESCs 1143 
cultured in presence of Activin or subjected to Activin/Nodal inhibition for 2h with SB (n=3 1144 
cultures). Note that the sum of the percentages within each graph does not add to 100% 1145 
because some m6A peaks overlap several feature types. MetDiff is an exome peak caller, and 1146 
accordingly 100% of peaks map to exons. MACS2 identifies peaks throughout the genome. 1147 
(d) Venn diagrams showing the overlap of peaks identified by the two pipelines. Only MetDiff 1148 
peaks that were also identified MACS2 were considered for subsequent analyses focused on 1149 
m6A peaks on exons. (e) Top sequence motifs identified de novo on all m6A exon peaks, or 1150 
on such peaks that showed significant downregulation following Activin/Nodal inhibition 1151 
(Activin/Nodal-sensitive m6A peaks; Supplementary Table 2). The position of the methylated 1152 
adenosine is indicated by a box. (f) Coverage profiles for all m6A exon peaks across the 1153 
length of different genomic features. Each feature type is expressed as 100 bins of equal length 1154 
with 5’ to 3’ directionality. (g-h) Overlap of m6A exon peaks to transcription start sites (TSS) 1155 
or transcription end sites (TES). In g, the analysis was performed for all m6A peaks. In h, only 1156 
Activin/Nodal-sensitive peaks were considered. (i) On the left, Activin/Nodal-sensitive m6A 1157 
exon peaks were evaluated for direct overlap with SMAD2/3 binding sites measured by ChIP-1158 
seq30. n=482 peaks; FDR=0.41 (non-significant at 95% confidence interval, N.S.) as 1159 
calculated by the permutation test implemented by the GAT python package. On the right, 1160 
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overlap was calculated after the same features were mapped to their corresponding transcripts 1161 
or genes, respectively. A significant overlap was observed for the transcript-gene overlap. 1162 
n=372 genes; hypergeometric test p-value (p) of 2.88E-18, significant at 95% confidence 1163 
interval. (j) m6A NeMeRIP-seq results for selected transcripts (n=3 cultures; replicates 1164 
combined for visualization). Coverage tracks represent read-enrichments normalized by 1165 
million mapped reads and size of the library. Blue: sequencing results of m6A NeMeRIP. 1166 
Orange: sequencing results of pre-NeMeRIP input RNA (negative control). GENCODE gene 1167 
annotations are shown (red: protein coding exons; white: untranslated exons; note that all 1168 
potential exons are shown and overlaid). The location of SMAD2/3 ChIP-seq binding sites is 1169 
also reported. Compared to the other genes shown, the m6A levels on SOX2 were unaffected 1170 
by Activin/Nodal inhibition, showing specificity of action. OCT4/POU5F1 is reported as 1171 
negative control since it is known not to have any m6A site23, as confirmed by the lack of 1172 
m6A enrichment compared to the input. 1173 
 1174 
Extended Data Figure 6. Features of Activin/Nodal-sensitive differential m6A deposition. 1175 
(a) Scatter plot of the average log2 fold-change (FC) in SB-431542 (SB) versus Activin-1176 
treated hESCs for m6A NeMeRIP-seq and pre-NeMeRIP input RNA (n=3 cultures). The 1177 
analysis was performed for all m6A exon peaks (left), or for such peaks significantly 1178 
downregulated following Activin/Nodal inhibition (right). Data was colour coded according to 1179 
the square of the difference between the two values (square diff.). (b-c) As in Extended Data 1180 
Fig. 5j, but for representative transcripts whose expression is stable following Activin/Nodal 1181 
inhibition for 2 hours (n=3 cultures; replicates combined for visualization). The m6A 1182 
NeMeRIP and input tracks were separated and have a different scale in order to facilitate 1183 
visual comparison between the conditions. The m6A peaks and those significantly 1184 
downregulated after SB treatment for 2h are indicated. (d) Venn diagram illustrating the 1185 
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strategy for the identification of m6A peaks on introns. Peaks mapping to the transcribed 1186 
genome were obtained by running MetDiff using an extended transcriptome annotation based 1187 
on the pre-NeMeRIP input RNA, which is abundant with introns. The resulting peaks were 1188 
first filtered by overlap with genome-wide MACS2-identified peaks, and then by lack of 1189 
overlap with annotated exons. (e) Results of MetDiff differential methylation analysis in 1190 
Activin vs SB 2h for m6A peaks on introns. n=3 cultures; p-value calculated by likelihood 1191 
ratio test implemented in the MetDiff R package, and adjusted to False Discovery Rate (FDR) 1192 
by Benjamini-Hochberg correction. See Supplementary Table 2 for the FDR of individual 1193 
peaks. abs. FC: absolute fold-change. (f) As in Extended Data Fig. 5j, but for a representative 1194 
transcript that shows Activin/Nodal-sensitive m6A deposition in introns (n=3 cultures; 1195 
replicates combined for visualization). The m6A peaks on exons, introns, and those 1196 
significantly downregulated after SB treatment within each subset are indicated. (g) Plots of 1197 
RPKM-normalized mean m6A coverage for m6A exon peaks significantly downregulated 1198 
after SB treatment (absolute fold-change>1.5). Data for all such peaks is in blue, while green 1199 
lines report coverage for only those peaks characterized by next generation sequencing reads 1200 
that span exon-intron junctions. Exons were scaled proportionally, and the position of the 3’ 1201 
and 5’ splice sites (SS) is indicated. A window of 500 base pairs (bp) on either side of the 1202 
splice sites is shown. m6A: signal from m6A NeMeRIP-seq; input: signal from pre-NeMeRIP 1203 
input RNA. The results show that coverage of Activin/Nodal-sensitive m6A peaks often spans 1204 
across splice sites (highlighted by the dotted lines). (h) Heatmap representing in an extended 1205 
form the data shown in panel g for all Activin/Nodal-sensitive m6A exon peaks in hESCs 1206 
cultured in presence of Activin. Multiple regions where sequencing coverage extends across 1207 
exon-intron junctions can be observed (see Supplementary Table 2). (i) Example of an 1208 
Activin/Nodal-sensitive peaks located in the proximity of a 3’ splice site (n=3 cultures; 1209 
replicates combined for visualization). This peak can be visualized within its genomic context 1210 
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in panel c, where it is indicated by a dotted box. Data plotted on top is m6A NeMeRIP-seq 1211 
coverage, while individual next generation sequencing reads are shown on the bottom. 1212 
Multiple reads spanning the exon-intron junction (indicated by the dashed line) can be 1213 
observed. (j) Relationship between the decrease of m6A on the most strongly affected exonic 1214 
peak located on a transcript (y axis) and the mean change of all other peaks mapping to the 1215 
same transcript (x axis). The analysis considered transcripts with multiple m6A peaks and with 1216 
at least one peak significantly decreasing after Activin/Nodal inhibition with SB (absolute 1217 
fold-change>1.5). Sensitivity of m6A deposition to Activin/Nodal signalling across these 1218 
transcripts correlated. 1219 
 1220 
Extended Data Figure 7. Generation and functional characterization of inducible 1221 
knockdown hPSCs for the subunits of the m6A methyltransferase complex. 1222 
(a) qPCR validation of tetracycline-inducible knockdown (iKD) hESCs cultured in presence 1223 
of tetracycline (TET) for 5 days to drive gene knockdown. Two distinct shRNAs (sh) and 1224 
multiple clonal sublines (cl) were tested for each gene. Expression is shown as normalized on 1225 
the average level in hESCs carrying a negative control scrambled (SCR) shRNA. For each 1226 
gene, sh1 cl1 was chosen for further analyses. The mean is indicated, n=2 cultures. (b) 1227 
Western blot validation of selected iKD hESCs for the indicated genes. TUB4A4 (α-tubulin): 1228 
loading control. Results are representative of three independent experiments. (c) m6A 1229 
methylated RNA immunoprecipitation (MeRIP)-qPCR in iKD hESCs cultured for 10 days in 1230 
absence (CTR) or presence of tetracycline (TET). m6A abundance is reported relative to 1231 
control conditions in the same hESC line. The mean is indicated, n=2 technical replicates. 1232 
Results are representative of two independent experiments. (d) m6A dot blot in WTAP or 1233 
SCR iKD hESCs treated as described in panel c. Decreasing amounts of mRNA were spotted 1234 
to facilitate semi-quantitative comparisons, as indicated. Results are representative of two 1235 
independent experiments. (e) Immunofluorescence for the pluripotency markers NANOG and 1236 
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OCT4 in iKD hESCs cultured for three passages (15 days) in absence (CTR) or presence of 1237 
tetracycline (TET). DAPI shows nuclear staining. Scale bars: 100μm. Results are 1238 
representative of two independent experiments. (f) Flow cytometry quantifications for 1239 
NANOG in cells treated as described for panel e. The percentage and median fluorescence 1240 
intensity (MFI) of NANOG positive cells (NANOG+) are reported. The gates used for the 1241 
analysis are shown, and were determined based on a secondary antibody only negative 1242 
staining (NEG). Results are representative of two independent experiments. 1243 
 1244 
Extended Data Figure 8. Function of the m6A methyltransferase complex during germ 1245 
layer specification. 1246 
(a) qPCR analysis following neuroectoderm or endoderm differentiation of inducible 1247 
knockdown (iKD) hESCs cultured in absence (CTR) or presence of tetracycline (TET). 1248 
Tetracycline treatment was initiated in undifferentiated hESCs for 10 days and was maintained 1249 
during differentiation (3 days). Expression is shown as normalized on the average level in 1250 
undifferentiated hESCs. Mean ± SEM, n=3 cultures. Significant differences vs same iKD line 1251 
in control conditions were calculated by 2-way ANOVA with post-hoc Holm-Sidak 1252 
comparisons: *=p<0.05, **=p<0.01, and ***=p<0.001. (b) Flow cytometry quantification of 1253 
the percentage of SOX1 positive cells (SOX1+) in cells treated as described for panel a. Mean 1254 
is indicated, n=2 cultures. (c) Immunofluorescent stainings for the lineage marker SOX17 in 1255 
endoderm-differentiated hESCs treated as described for panel a. DAPI shows nuclear staining. 1256 
Scale bars: 100μm. Results are representative of two independent experiments. (d) qPCR 1257 
validation of multiple inducible knockdown (MiKD) hESCs simultaneously expressing 1258 
shRNAs against WTAP, METTL3 (M3), and METTL14 (M14). Cells expressing three copies 1259 
of the scrambled shRNA (SCR3x) were used as negative control. Cells were cultured in 1260 
presence of tetracycline (TET) for 5 days to drive gene knockdown. Mean ± SEM, n=3 1261 
cultures. Significant differences vs SCR3x hESCs in control conditions were calculated by 2-1262 
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way ANOVA with post-hoc Holm-Sidak comparisons: ***=p<0.001. (e-f) qPCR analysis 1263 
following endoderm differentiation of WTAP, METTL3, and METTL14 MiKD hESCs treated 1264 
as described for panel a. Mean ± SEM, n=3 cultures. Significant differences versus control 1265 
conditions were calculated by two tailed t-test (panel e) or  2-way ANOVA with post-hoc 1266 
Holm-Sidak comparisons (panel f): **=p<0.01, and ***=p<0.001. 1267 
 1268 
Extended Data Figure 9. Function of the m6A methyltransferase complex during 1269 
pluripotency exit induced by Activin/Nodal inhibition. 1270 
(a) qPCR analyses in inducible knockdown (iKD) hESCs cultured in absence (CTR) or 1271 
presence of tetracycline (TET) for 10 days, then subjected to Activin/Nodal signalling 1272 
inhibition with SB-431542 (SB) for the indicated time (see Extended Data Fig. 10a). Activin: 1273 
cells maintained in standard pluripotency-promoting culture conditions containing Activin and 1274 
collected at the beginning of the experiment. Mean ± SEM, n=3 cultures. Significant 1275 
differences vs same iKD line in control conditions were calculated by 2-way ANOVA with 1276 
post-hoc Holm-Sidak comparisons: **=p<0.01, and ***=p<0.001. (b) Western blots of cells 1277 
treated as described in panel a. TUBA4A (α-tubulin): loading control. Results are 1278 
representative of two independent experiments. (c) Measurement of mRNA stability in WTAP 1279 
iKD hESCs cultured in absence (CTR) or presence of tetracycline (TET) for 10 days. Samples 1280 
were collected following transcriptional inhibition using Actinomycin D (ActD) for the 1281 
indicated time. The statistical significance of differences between the mRNA half-lives in TET 1282 
vs CTR is reported (n=3 cultures, comparison of fits to one phase decay model by extra sum-1283 
of-squares F test). The difference was significant for NANOG but not SOX2 (95% confidence 1284 
interval). (d) Model showing the interplays between Activin/Nodal signalling and m6A 1285 
deposition in hPSCs (left), and the phenotype induced by impairment of the m6A 1286 
methyltransferase complex (right). 1287 
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 1288 
Extended Data Figure 10. Genome wide analysis of the relationship between WTAP and 1289 
Activin/Nodal signalling. 1290 
(a) Schematic of the experimental approach to investigate the transcriptional changes induced 1291 
by the knockdown of the m6A methyltransferase complex subunits during neuroectoderm 1292 
specification of hESCs. (b) qPCR analyses of WTAP inducible knockdown (iKD) hESCs 1293 
subjected to the experiment illustrated in panel a (n=3 cultures). Activin: cells maintained in 1294 
standard pluripotency-promoting culture conditions containing Activin and collected at the 1295 
beginning of the experiment.  SB: SB-431542. Z-scores indicate differential expression 1296 
measured in number of standard deviations from the average across all time points. (c) RNA-1297 
seq analysis at selected time points from the samples shown in panel b (n=3 cultures). The 1298 
heatmap depicts Z-scores for the top 5% differentially expressed genes (1789 genes as ranked 1299 
by the Hotelling T2 statistic). Genes and samples were clustered based on their Euclidean 1300 
distance, and the four major gene clusters are indicated (see the Supplementary Discussion). 1301 
(d) Expression profiles of genes belonging to the clusters indicated in panel c. Selected results 1302 
of gene enrichment analysis and representative genes for each cluster are reported (cluster 1: 1303 
n=456 genes; cluster 2: n=471 genes; cluster 3: n=442 genes; cluster 4: n=392 genes; Fisher’s 1304 
exact test followed by Benjamini-Hochberg correction for multiple comparisions). (e) 1305 
Principal component analysis (PCA) of RNA-seq results described in panel c (n=3 cultures). 1306 
The top 5% differentially expressed genes were considered for this analysis. For each of the 1307 
two main principal components (PC1 and PC2), the fraction of inter-sample variance that they 1308 
explain and their proposed biological meaning are reported. (f) Proportion of transcripts 1309 
marked by at least one high-confidence m6A peak23 in transcripts significantly up- or 1310 
downregulated following WTAP inducible knockdown in hESCs maintained in presence of 1311 
Activin (left), or following Activin/Nodal inhibition for 2 hours with SB in control cells 1312 
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(right). Differential gene expression was calculated on n=3 cultures using the negative 1313 
binomial test implemented in DEseq2 with a cutoff of p<0.05 and abs.FC>2. The number of 1314 
genes in each group and the hypergeometric probabilities of the observed overlaps with m6A-1315 
marked transcripts are reported (n.s.: non-significant at 95% confidence interval). 1316 
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